Contenu connexe Similaire à CDE innate response for targets webinar (20) Plus de Defence and Security Accelerator (20) CDE innate response for targets webinar 3. The aim of CDE
Technology
Best providers
Barriers
9. Dstl is part of the
Ministry of Defence
UNCLASSIFIED / For Public Release
Centre for Defence Enterprise
www.science.mod.uk/enterprise cde@dstl.gov.uk
Crown Copyright Dstl 2012
Enduring challenges
• protection
• situational awareness
• power
• communications
• data
• lethality
• mobility
• human performance
• lower cost of ownership
• new capabilities
11. Dstl is part of the
Ministry of Defence
UNCLASSIFIED / For Public Release
Centre for Defence Enterprise
www.science.mod.uk/enterprise cde@dstl.gov.uk
Crown Copyright Dstl 2012
Read available
information
Start with –
Quick Start Guide
CDE Portal
13. Dstl is part of the
Ministry of Defence
UNCLASSIFIED / For Public Release
Centre for Defence Enterprise
www.science.mod.uk/enterprise cde@dstl.gov.uk
Crown Copyright Dstl 2012
Register now
16. Key dates
• Competition launches today
• Presentation to follow
• Opportunity for Q&A
• Webinar Tuesday 1 April
• Deadline for applications Thursday 5 June 2014 at 17:00 hrs
via Centre for Defence Enterprise Portal
• Funding decisions to be made July 2014
• Notifications end July
© Crown copyright 2014 Dstl
20 May 2014
17. Background: biothreat agents
• Pathogenic for man or animals
• Very low infectious dose
• Infectious via the inhalational route
• Cause endemic disease around world
• Usually are zoonotic diseases
• Lethal or incapacitating
© Crown copyright 2014 Dstl
20 May 2014
18. © Crown copyright 2014 Dstl
20 May 2014
Defence against biothreats
• Many potential biothreat agents
• How to defend against them?
• Impossible to make a vaccine/therapy for every
potential agent
• Require generic therapy
19. Generic approach to therapy
• By influencing the host response
• Requires an understanding of the host response to pathogen & safe
ways to influence it
• Requires identification of relevant targets or pathways in the host
20 May 2014
© Crown copyright 2014 Dstl
20. Innate (host) response targets for therapy
• Objective of this competition is to look broadly across research and
development to identify host cell targets and pathways
• Using data derived from diverse infection models
• Respondents to competition do not need to work directly with
biothreat agents
• Ultimate aim is to apply the most innovative approaches to biothreat
agents
20 May 2014
© Crown copyright 2014 Dstl
21. CDE themed competition specifics
• Seeking innovative proposals for short projects (<1year); £30-
80k guide; (£500k total budget)
• Show proof-of-concept for your proposal; there is funding
allocated for follow-on work for successful projects
• Competition divided into 3 challenges
• Respondents need to address 1 of the challenges, may address
>1, do not have to address all 3
• Challenges described fully in the competition document
• Bids must be ethical and compliant with UK government
legislation
20 May 2014
© Crown copyright 2014 Dstl
22. Challenge 1
© Crown copyright 2014 Dstl
20 May 2014
Identification of new cellular or host pathway targets
23. Identification of new cellular or host pathway
targets
• In host-pathogen model of your choice
– Does not need to be a biodefence pathogen
– Does not need to be in vivo
• Conditioning of cells ex vivo
eg to profile responses or prior to adoptive transfer
• Targeting cells in situ eg
– to refocus them
– to activate them
– to induce them to traffic
– to redirect them
© Crown copyright 2014 Dstl
20 May 2014
24. Identification of new cellular or host pathway
targets
May involve the identification of eg
• immuno stimulants
• modulators
• transfection factors
• chemokines, cytokines
or the induction (or blockade) of these
• cytokine/chemokine/growth factor receptors
and application of these to modulate host
responses
© Crown copyright 2014 Dstl
20 May 2014
25. Identification of new cellular or host pathway
targets
• Some of these may be
exogenous and some
endogenous factors
• Some endogenous natural
regulators /regulatory
pathways may be exploited
• to reduce inflammation
and to restore homeostasis
© Crown copyright 2014 Dstl
20 May 2014
Normal
OveractiveUnderactive
26. Possible outcomes
Proposals for
– identification of new cellular targets /pathways
– new applications of manipulating known cellular targets/pathways
– demonstration that targets may be influenced beneficially, for
example to:
• prevent cytotoxicity
• prevent/reduce microbial invasion
• reduce microbial load
• restore normal cell function
© Crown copyright 2014 Dstl
20 May 2014
28. Identification of new candidate therapies
Exploit appropriate cellular targets and pathways to
identify new therapies by, for example:
• enhancing cell-mediated immunity
• investigating novel combinations
• identification and manipulation of significant
transcription factors
• micro RNA-directed therapies or antagonists
© Crown copyright 2014 Dstl
20 May 2014
29. Possible outcomes
• Candidate therapies should be druggable and generic
• Proposals should show proof-of-concept
• Does not exclude the re-purposing or augmentation of existing
therapies
© Crown copyright 2014 Dstl
20 May 2014
31. Identification of new platform technologies
For assessing therapeutic benefit
• Novel technologies such as:
• non-invasive methods of in-vivo/ex-vivo
analysis eg bio-imaging or tracking
• Transcriptomics including micro RNA analysis
• In-silico modelling of host responses
• Novel assays to monitor the host immune response
© Crown copyright 2014 Dstl
20 May 2014
32. Possible outcomes
• New technologies which may facilitate the identification and
development of candidate therapies
• Proposals should demonstrate the impact of the technology
on therapeutic development
© Crown copyright 2014 Dstl
20 May 2014
33. What we want
• Highly innovative approaches that are significantly different from
existing technologies
• Generally technology readiness level (TRL) ≤ 3
• Generic approaches (not pathogen specific)
• Approaches applicable to intracellular pathogens where
appropriate
• Approaches that will lead to a feasible clinical product
© Crown copyright 2014 Dstl
20 May 2014
34. What we don’t want
Proposals that concern:
• high technology readiness level (TRL) capability
• serological targets only (rather than cellular)
• antibody-based therapies (but antibodies as a targeting
mechanism are acceptable)
• existing solutions or technology already tested and found to
have limited utility
• a paper study or review or similar
• pre-exposure therapies or therapeutics
• topical therapies for wounds
© Crown copyright 2014 Dstl
20 May 2014
35. Successful proposals
• Each will be assigned a Technical Partner
– Provides interface between project and defence community
– If project successful, potential routes to exploitation
developed
© Crown copyright 2014 Dstl
20 May 2014
36. Summary
• Competition launches today
• Webinar Tuesday 1 April
• Closes on Thursday 5 June 2014 at 17:00 hrs
• Short proof-of-concept proposals
• If successful, potential for follow-on funding
• May include additional research to develop technology for MOD
• Competition information available on CDE website
www.science.mod.uk
© Crown copyright 2014 Dstl
20 May 2014
38. Dstl is part of the
Ministry of Defence
UNCLASSIFIED / For Public Release
Centre for Defence Enterprise
www.science.mod.uk/enterprise cde@dstl.gov.uk
Crown Copyright Dstl 2012
e: cde@dstl.gov.uk
w: www.science.mod.uk
@dstlmod #dstlcde
LinkedIn group – search ‘Centre for
Defence Enterprise’
Keep in touch